

CURRICULUM VITAE

Reshma Lillaney Mahtani, D.O.

Assistant Professor, Division of Hematology/Oncology
Sylvester Comprehensive Cancer Center
University of Miami Health System
1192 East Newport Center Drive
Deerfield Beach, FL 33442
Office Phone: (954) 698-3639
Fax: (954) 571-0118
Email: RMahtani@med.miami.edu

Date of Birth: September 1, 1972

Citizenship: U.S.A.

Positions: Assistant Professor, Division of Hematology/Oncology
Sylvester Comprehensive Cancer Center, Deerfield Beach, FL
August 2010 - PRESENT

Physician, Hematology/Oncology
Boca Raton Comprehensive Cancer Center, Boca Raton, FL
October 2007 – April 2010

Director of Clinical Research
Boca Raton Comprehensive Cancer Center, Boca Raton, FL
January 2009 – April 2010

Board Certified: Hematology, 2008
Certified 10/27/08, Certificate valid through 12/31/2018

Medical Oncology, 2007
Certified 11/13/07, Certificate valid through 12/13/2017

American Board of Internal Medicine, 2004
Certified 08/24/2004, Certificate valid through 12/31/14
Re-certified 5/19/2014, Certificate valid through 12/31/24

Doctor of Osteopathy: University of New England College of Osteopathic Medicine, 2001

Master of Science: University of Connecticut, Neuroscience, 1997

Bachelor of Arts: Mount Holyoke College, Neuroscience, 1994

Awards and Honors: Sigma Sigma Phi Honor Society, 1997
Graduated with High Honor (Mount Holyoke College), 1994
Howard Hughes Research Fellowship, 1994 - 1995

Professional Societies: American Society of Clinical Oncology
American Society of Hematology

Post Graduate Training:

07/01 – 06/02 Internship: Greenwich Hospital (Yale-affiliate) - Greenwich, CT

07/02 – 06/04 Residency: St.Vincent's Catholic Medical Center - New York, NY

07/04 – 07/07 Fellowship: St.Vincent's Catholic Medical Center - New York, NY

PROFESSIONAL ORGANIZATIONS:

American Society of Clinical Oncology
Eastern Cooperative Oncology Group

PROFESSIONAL ACTIVITIES:

Intramural:

2014- present: Data Safety Monitoring Committee Member, University of Miami

2014- present: Clinical Trials Acceleration Grant Review Committee, University of Miami

2014- present: Chief of GYN Cytology Search Committee, University of Miami

Extramural:

2015 – present: Editorial Board Member, *The Breast Journal*

2015 – present: Member, Breast Cancer Core Committee, Eastern Cooperative Oncology Group (ECOG)

Ad Hoc Journal Reviewer:

Journal of Clinical Oncology, Lung Cancer, Future Oncology

PUBLIC SPEAKING EXPERIENCE

Genentech, Ortho Biotech – Member of speaker's bureau (2008-2010)

Gilda's Club – Panel and individual speaker for an organization whose mission is to become the premier emotional and social support community for individuals with cancer.

FORCE (Facing Our Risk of Cancer Empowered) - Speaker for an organization whose mission is to be a resource for patients with a high risk for breast and ovarian cancer due to genetic predisposition, family history, or other factors.

CONTINUING MEDICAL EDUCATION SPEAKING AND POSITIONS:

Medical Director – Best of ASCO, Philadelphia, 2016

Medical Director – Best of ASCO Puerto Rico, 2015

Speaker – Best of ASCO Puerto Rico, 2014 (Topic: Extended Endocrine Therapy for Breast Cancer)

Speaker – Synergy Meeting 2014 (Topic: Biologics in Metastatic Colorectal Cancer)
Synergy Meeting 2015 (Topic: Medical Management of MBC and the Role of Interventional Oncology)

Meeting Moderator – Great Debates in Hematology, 2012 and 2013

PUBLICATIONS:

1. Zeichner S, Ambros T, Zaravinos J, Montero A, **Mahtani R.**, Ahn E, Vogel C. Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse. *Breast Cancer: Basic and Clinical Research* (vol 9) 1-9, 2015
2. Miller K, Diéras V, Harbeck N, Andre F, **Mahtani R.**, Gianni L, Albain K, Crivellari D, Liang F, Michelson G, Burris H. Phase IIa Trial of Trastuzumab Emtansine (T-DM1) With Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer. *Journal of Clinical Oncology* (vol 32) 1437-1445, 2014
3. Savas J, **Mahtani R.** Skin Diseases in the Immunocompromised, Chapter 8: Cutaneous Complications of Chemotherapy. Edited by John C. Hall (in press)
4. Modi S, Saura C, Henderson C, Lin NU, **Mahtani R.**, Goddard J, Rodenas E, Hudis C, O'Shaughnessy J, Baselga J. A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. *Breast Cancer Res Treat.* 2013 Apr 12.
5. Vogel C, **Mahtani R.** Patterns of Care: Breast Cancer in the 21st Century. *Managed Care Pathways 1* (vol2) 18-22, 2012
6. Vogel C, **Mahtani R.** Evolution of Targeted Therapies for Breast Cancer in the 21st Century. *Managed Care Pathways 1* (vol2) 23-26, 2012
7. Ambros T, Zeichner S, Zaravinos J, Montero A, Ahn E, Mani A, Kronish L, **Mahtani R.**, Vogel C. Low-dose capecitabine monotherapy in HER-2 negative metastatic breast cancer: a retrospective study. *Cancer Research*: December 15, 2012; Volume 72, Issue 24, Supplement 3
8. Sandoval J, **Mahtani R.**, Gluck S. HER2-positive metastatic breast cancer: a double-edged sword. *Breast Cancer Management* Vol 1, No. 3, 181-184, 2012
9. **Mahtani R.**, Khan R., Jahanzeb, M. The Potential Application of Zolendronic Acid as Anticancer Therapy in Patients with Non-Small Cell Lung Cancer. *Clinical Lung Cancer* Vol 12, No 1, 26-32, 2011.
10. **Mahtani R.**, Jahanzeb, M. Bisphosphonates as Anticancer Therapy for Early Breast Cancer, *Clinical Breast Cancer* Vol. 10, No. 5, 359-366, 2010

11. Vogel C, **Mahtani R**. Associate Guest Editors, *Clinical Therapeutics, Volume 31, Part2, 2009*
12. **Mahtani R**. Vogel, C. High-Dose Estrogen as Salvage Hormonal Therapy for Highly Refractory Metastatic Breast Cancer: A Retrospective Chart Review. *Clinical Therapeutics, Volume 31, Part 2, Theme Issue 2009: 2371-2378*.
13. **Mahtani R**. Managing Care in the Cervical Cancer Patient. *Managed Care Oncology, Quarter 2 2009: 15-22*.
14. **Mahtani R**. Screening, Diagnosis and Treatment Considerations for Ovarian Cancer. *Managed Care Oncology, Quarter 4, 2008: 13-16*.
15. **Mahtani R.**, Vogel C. Three Pleomorphic Lobular Carcinomas of the Breast - Long Term Responders to Herceptin. Coincidence or a Hint? *Journal of Clinical Oncology – (Correspondence) Dec 10, 2008: 5823-5824*.
16. **Mahtani R**, Macdonald J. Mechanisms of Synergy for Cetuximab and Chemotherapy in Tumors of the Gastrointestinal Tract. *The Oncologist, 2008. Vol 13(1): 39-47*.
17. Gurvits G, **Mahtani R**, Halperin I. Hepatitis C virus and splenic marginal zone lymphoma with villous lymphocytes: Away from conventional therapy. *Scandanavian Journal of Gastroenterology, 2007. Volume 42(11); 1392-1393*.
18. **Mahtani R**, Waltzman R, Macdonald J. Gastric Cancer: Adjuvant Therapy. In: Macdonald, J., ed. *Advances in the Management of Gastric Cancer*. New York. *CMPMedica, 2006:35-53*.
19. **Lillaney R**, Maher T, Chaiyuakul R, and Ally A. Changes in extracellular glutamate and pressor response during muscle contraction following AMPA-receptor blockage in the RVLM and CVLM. *Brain Research 844(1999) 164-173*
20. Freda B, Gaitonde R, **Lillaney R**, and Ally A. Cardiovascular responses to muscle contraction following microdialysis of nitric oxide precursor into ventrolateral medulla. *Brain Research 828(1999) 60-67*
21. Deckel W, **Lillaney R**, Ronan P, Summers C. Lateralized effects of ethanol on aggression and serotonergic systems in *Anolis carolinensis*. *Brain Research 807(1998) 38-46*

ABSTRACTS

1. Ambros T, Zeichner S, Zaravinos J, Montero A, Ahn E, Mani A, Kronish L, **Mahtani R**, and Vogel C. Low-dose capecitabine monotherapy in HER-2 negative metastatic breast cancer: a retrospective study. *Cancer Research: December 15, 2012; Volume 72, Issue 24, Supplement 3*
2. Modi S, Saura C, Henderson C, Lin N, **Mahtani R**, Goddard J, Rodenas E, O'Shaughnessy J, Baselga J. Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer. ASCO 2011, Abstract# 7511

3. Miller K, Gianni L, Andre F, Dieras V, **Mahtani R**, Harbeck N, Huang J, Shih T, Choi Y, Burris H. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). *J Clin Oncol* 28:15s, ASCO 2010 (suppl; abstract 1012)
4. **Mahtani, R**, Stein A, and Vogel C.L. High dose estrogen as a salvage hormonal strategy for highly refractory metastatic breast cancer (MBC): "Back to the Future." *San Antonio Breast Conference Abstract #6129 (2008)*
5. **Mahtani, R**, Resigno, J, Klein, P, Bernik S, Mohammed A, and Ying, B. Clinicopathologic factors associated with microinvasion in DCIS: Possible utility in planning sentinel lymph node biopsy. *San Antonio Breast Conference Abstract #3024 (2007)*
6. **Lillaney R**, Maher T, Reidman D, Christopher M, Yon T, Ally A. Does rostral or caudal ventrolateral medullary AMPA-receptor antagonism modulate cardiovascular responses via altering extracellular glutamate levels during muscle contraction? *The FASEB Journal*, 13:1999
7. Christopher M, Maher T, Reidman D, **Lillaney R**, Bhole G, Ally A. Does rostral ventrolateral medullary 5-HT_{1A}-receptor activation attenuate cardiovascular responses via altering extracellular glutamate levels during muscle contraction? *The FASEB Journal*, 13:1999
8. Reidman D, Maher T, **Lillaney R**, Christopher M, Yon T, Ally A. Effects of rostral ventrolateral medullary NMDA-receptor antagonism on cardiovascular responses and extracellular glutamate during muscle contraction. *The FASEB Journal*, 13:1999
9. Shoemaker W, **Lillaney R**, and Hebert D. Lateralized neurotransmitter levels and turnover: relationship to voluntary ethanol drinking. *Society for Neuroscience Abstracts* 23:2399, 1997
10. Shoemaker W, Deckel W, Hebert D, **Lillaney R**. Effects of a single dose of DMI on voluntary ethanol drinking and lateralized monoamine levels. *Society for Neuroscience Abstracts*, 1996

INVESTIGATOR-INITIATED TRIALS:

Supported by Genenetch:

A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine with Trastuzumab Emtansine in Pre-Treated Metastatic Breast Cancer

- 8. Pfizer B2151007** **AN OPEN LABEL, MULTI CENTER, RANDOMIZED PHASE 1B/2 STUDY OF PF05212384 PLUS 5FLUOROURACILLEUCOVORINIRINOTECAN (FOLFIRI) VERSUS BEVACIZUMAB PLUS FOLFIRI IN METASTATIC COLORECTAL CANCER**

- 9. HOG** **PARP Inhibition After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer on ER/PR, HER2 Negative with Known BRCA 1/2 Mutations: Hoosier Oncology Group BRE09146**

- 10. Genentech TH3RESA** **A Phase II Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine (T-DM1) Compared With Treatment of Physician's Choice in Patients with HER2-Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy**

- 11. Kyowa US-002** **A Phase 1/2 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of KW-2450 in Combination with Lapatnib and Letrozole in Subjects with Advanced or Metastatic Breast Cancer whose Tumors Overexpress HER2**

- 12. AVEO** **Tivozanib Hydrochloride in Combination with Paclitaxel Versus Placebo with Paclitaxel in Patients with Locally Recurrent of Metastatic Triple Negative Breast Cancer**

- 13. Amgen 20062042** **An Open-Label Study of AMG 386 in Combination with Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects with HER2-positive Locally Recurrent or Metastatic Breast Cancer**

- 14. AstraZeneca D0810C00012A** **Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Compare the Safety and Efficacy of Two Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-Based Chemotherapy.**

- 15. TDM4374g** **A Phase II, Single-Arm, Open-Label Study Of Trastuzumab-MCC-DM1 Administered Intravenously To Patients With Her2-Positive Metastatic Breast Cancer**

- 16. Genentech AVF4349n** **An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer**

- 17. IPI-504-07:** **A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of IPI-504 in Combination with Trastuzumab in Patients with Pretreated, Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer**

- 17. NCCTG - N0733** **Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane**

- 18. Protocol CFEM345DUS59** **Open-label, single-arm, multicenter study to evaluate the rheumatological tolerability of Letrozole as an adjuvant breast cancer treatment in postmenopausal women who are intolerant and discontinue Anastrozole due to grade 2-3 arthralgia-myalgia**

- 19. NSABP B-27** **A Randomized Trial Comparing Preoperative Doxorubicin (Adriamycin) Cyclophosphamide (AC) to Preoperative AC Followed by Preoperative Docetaxel (Taxotere) and to Preoperative AC Followed by Postoperative Docetaxel in Patients with Operative Carcinoma of the Breast**

- 20. NSABP B-30** **A Three-arm randomized trial to compare adjuvant Adriamycin and cyclophosphamide followed by Taxotere (AC à T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere, Cyclophosphamide (ATC) in Breast Cancer Patients with Positive Axillary Lymph Nodes**

- 21. NSABP B-43** **A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy**

- 22. SWOG - S0702** **A Prospective Observational Multicenter Cohort Study To Assess The Incidence Of Osteonecrosis Of The Jaw (Onj) In Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment**

- 23. CALGB 40502** **A Randomized Phase III trial of Weekly Paclitaxel Compared to Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.**
- 24. Eisai - E7389-G000-209** **A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer**
- 25. Novartis - CRAD001Y2301** **A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive, Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole.**
- 26. SCRI - TITAN - BRE 145** **Phase III Study of Doxorubicin/Cyclophosphamide (AC) followed by Ixabepilone vs. AC followed by Paclitaxel in Patients with Triple-Negative Early-Stage Breast Cancer. [TITAN]**
- 27. EMD Serono** **A randomized, double-blind, controlled phase III study of Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy of post-menopausal women with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, inoperable locally advanced, recurrent, or metastatic breast cancer - “STRIDE - Stimulating immune Response In aDvanced brEast cancer”**
- 28. SWOG - S0715:** **Randomized Placebo-Controlled Trial of Acetyl L-Carnitine for the Prevention of Taxane Induced Neuropathy**

PRIOR EXPERIENCE:

Research Assistant: University of Connecticut Health Center, Farmington, CT 1995 - 1997
Planned and executed research projects relating to the behavioral and structural effects of alcohol in several animal models.

Emergency Medical Technician: Rocky Hill Ambulance Association, Rocky Hill, CT 1995-1997

Research Assistant: Massachusetts General Hospital, Boston, MA 1994-1995
Participated in translational research projects in HIV medicine.
Proficient in blood culturing, ELISA, HPLC, immunofluorescence assays and radioimmunoassays.

Pharmaceutical Technician: Cromwell Pharmacy, Cromwell, CT 1989-1994